New drug-free device meets unmet need

LONDON, ON, Sept. 9, 2014 /CNW/ - New study results presented today at the European Respiratory Society (ERS) Conference in Munich Germany provide further evidence that the Aerobika* OPEP device developed by Trudell Medical International (TMI) provides an important treatment for the 250 million patients suffering from COPD globally.

Many of these patients suffer from excessive mucus resulting in breathlessness, the inability to do everyday activities, and decreased quality of life.  When mucus is not cleared from the lungs it can become a breeding ground for bacteria and infections, often leading to exacerbations, hospitalizations and even death.  In 2010, the cost of COPD in the USA alone was projected to be approximately US$50 billion with hospitalization accounting for the majority of these costs.  No current drug treatments address mucus clearance. 

Study indicates important benefits of non-drug therapy

The study conducted at The Robarts Research Institute, affiliated with the Schulich School of Medicine, Western University, London Canada, demonstrated that after 3 weeks of daily use of the Aerobika* device, there were statistically significant improvements in clinical and patient reported outcomes including increased mucus clearance, a decrease in cough frequency and breathlessness, and increased exercise tolerance.  Overall quality of life was also improved.  There were no adverse events reported while using the device.

"The results from this study provide compelling evidence that patients suffering from COPD or Bronchiectasis now have a safe and easy-to-use method to address the unmet need of mucus clearance and improve their quality of life", states Dr. Jason Suggett, Group Director, Science and Technology, TMI. "We are also excited about the future possibility of looking at the longer term impact on patient outcomes and healthcare system efficiencies". 

How it works

The Aerobika* is a hand-held, easy-to-use, drug-free device with a unique proprietary pressure-oscillation dynamic.  When the patient exhales through the device, intermittent resistance creates positive pressure and oscillations simultaneously, which mobilizes and assists mucociliary clearance to the upper airways where it can be coughed out.

Aerobika* is available in Canada, the US (Monaghan Medical Corporation), Mexico, and select European countries including Germany.  The global launch will continue through 2014.  For more information as well as image and video downloads, please visit

Conference Alert:  Visit Trudell Medical International (TMI) at ERS International Conference 2014 in Hall B1 Stand D.03 for a demonstration of the product and to learn more about the study.  

About Trudell Medical International

Trudell Medical International (TMI) designs, develops and manufactures innovative medical devices, including the flagship AeroChamber* Brand of Valved Holding Chamber (VHC) and the latest MDEA gold winner, Aerobika* OPEP therapy system for COPD patients.  Our best-in-class respiratory management products are sold in over 100 countries worldwide and their efficacy has been validated in over 500 publications. For more information, please visit us on the web at

Video with caption: "Video: A video illustrating what is happening in the lungs while using the Aerobika* Oscillating PEP device and why it is helpful". Video available at:

SOURCE: Trudell Medical International

For further information: Mark Pickard, Vice President and General Manager, 519-455-7060, ext. 2200;, Website:


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890